ECSP22016558A - Proteínas de fusión terapéuticas - Google Patents

Proteínas de fusión terapéuticas

Info

Publication number
ECSP22016558A
ECSP22016558A ECSENADI202216558A ECDI202216558A ECSP22016558A EC SP22016558 A ECSP22016558 A EC SP22016558A EC SENADI202216558 A ECSENADI202216558 A EC SENADI202216558A EC DI202216558 A ECDI202216558 A EC DI202216558A EC SP22016558 A ECSP22016558 A EC SP22016558A
Authority
EC
Ecuador
Prior art keywords
acute
fusion proteins
chronic
therapeutic fusion
injuries
Prior art date
Application number
ECSENADI202216558A
Other languages
English (en)
Inventor
Laurent Klein
Darko Skegro
Marco Villani
Karl Welzenbach
Sebastien Irigaray
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22016558A publication Critical patent/ECSP22016558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H04W4/025—Services making use of location information using location based information parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H04W4/029—Location-based management or tracking services
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Telephone Function (AREA)

Abstract

La presente invención se refiere a proteínas de fusión adecuadas para su uso como medicamento o herramienta de investigación. Los usos terapéuticos de las proteínas de fusión pueden incluir la prevención o el tratamiento de trastornos inflamatorios agudos o crónicos y microvasculares y de órganos impulsados por el sistema inmunitario, por ejemplo, lesión renal aguda, infarto agudo de miocardio, dificultad respiratoria aguda o enfermedad pulmonar obstructiva crónica, fibrosis y otras lesiones de órganos resultantes de traumatismos de tejidos y lesiones agudas y crónicas.
ECSENADI202216558A 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas ECSP22016558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06

Publications (1)

Publication Number Publication Date
ECSP22016558A true ECSP22016558A (es) 2022-04-29

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI202216180A ECSP22016180A (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas
ECSENADI202216558A ECSP22016558A (es) 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSENADI202216180A ECSP22016180A (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas

Country Status (20)

Country Link
US (3) US20230220048A1 (es)
EP (3) EP4025237A1 (es)
JP (3) JP2022547050A (es)
KR (3) KR20220058586A (es)
CN (3) CN114341194A (es)
AR (2) AR119905A1 (es)
AU (3) AU2020343926A1 (es)
BR (2) BR112022003762A2 (es)
CA (3) CA3152990A1 (es)
CO (2) CO2022002567A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220015A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220055A1 (es)
MX (2) MX2022002638A (es)
PE (2) PE20220401A1 (es)
TW (2) TW202122414A (es)
WO (3) WO2021044362A1 (es)
ZA (2) ZA202201827B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022509445A (ja) * 2018-10-25 2022-01-20 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
EP4326307A1 (en) * 2021-04-22 2024-02-28 Biolegend, Inc. Phosphatidylserine binding agents for the detection and depletion of phosphatidylserine positive cells
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
WO2024080854A1 (en) * 2022-10-14 2024-04-18 Illimis Therapeutics, Inc. Fusion molecule and method for treating immunological diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2006243905B2 (en) 2005-05-13 2011-09-01 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor VIII and sepsis
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2215264B1 (en) * 2007-11-15 2015-04-01 The Feinstein Institute for Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
WO2012149254A2 (en) 2011-04-28 2012-11-01 The Feinstein Institute For Medical Research Mfg-e8 and uses thereof
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
SG11201602289WA (en) 2013-08-23 2016-05-30 Riken Polypeptide exhibiting fluorescent properties, and utilization of same
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
CN106537795B (zh) * 2014-03-31 2021-10-01 英国电讯有限公司 数据通信
WO2015175512A1 (en) * 2014-05-15 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
WO2018158719A1 (en) * 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
US11028139B2 (en) 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
JP2022509445A (ja) 2018-10-25 2022-01-20 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法

Also Published As

Publication number Publication date
CN114341195A (zh) 2022-04-12
WO2021044361A1 (en) 2021-03-11
PE20220401A1 (es) 2022-03-22
KR20220058585A (ko) 2022-05-09
CU20220015A7 (es) 2022-10-11
CU20220016A7 (es) 2022-10-11
KR20220058586A (ko) 2022-05-09
AR119902A1 (es) 2022-01-19
EP4025237A1 (en) 2022-07-13
WO2021044360A1 (en) 2021-03-11
IL290675A (en) 2022-04-01
CR20220096A (es) 2022-05-11
JOP20220055A1 (ar) 2023-01-30
CA3152499A1 (en) 2021-03-11
CN114341194A (zh) 2022-04-12
CN114302896A (zh) 2022-04-08
CO2022002567A2 (es) 2022-04-08
BR112022003762A2 (pt) 2022-05-31
JOP20220058A1 (ar) 2023-01-30
EP4025239A1 (en) 2022-07-13
ZA202201828B (en) 2023-10-25
JP2022547050A (ja) 2022-11-10
ECSP22016180A (es) 2022-04-29
CR20220089A (es) 2022-03-30
ZA202201827B (en) 2023-11-29
AU2020343926A1 (en) 2022-04-07
AU2020343512A1 (en) 2022-04-07
US20230265160A1 (en) 2023-08-24
IL290660A (en) 2022-04-01
EP4025238A1 (en) 2022-07-13
AR119905A1 (es) 2022-01-19
JP2022547111A (ja) 2022-11-10
JP2022547051A (ja) 2022-11-10
PE20221051A1 (es) 2022-06-30
BR112022003745A2 (pt) 2022-05-31
US20230308835A1 (en) 2023-09-28
US20230220048A1 (en) 2023-07-13
MX2022002637A (es) 2022-03-25
IL290618A (en) 2022-04-01
AU2020340618A1 (en) 2022-04-07
CO2022002545A2 (es) 2022-04-08
TW202122415A (zh) 2021-06-16
TW202122414A (zh) 2021-06-16
MX2022002638A (es) 2022-03-25
CA3152500A1 (en) 2021-03-11
KR20220058588A (ko) 2022-05-09
CA3152990A1 (en) 2021-03-11
WO2021044362A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
ECSP22016558A (es) Proteínas de fusión terapéuticas
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
ECSP17033565A (es) Cromanos sustituidos y métodos para su uso
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
CL2015001163A1 (es) Compuestos derivados de imidazo[1,2-a]piridincarboxamidas aminosustituidas; procedimiento para prepararlos; medicamento; procedimiento para el tratamiento y/o la prevencion; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina de pecho, hipertension e hipertension pulmonar, entre otras enfermedades.
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CY1123011T1 (el) Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
BRPI0516626A (pt) pteridinas substituìdas e uso das mesmas
AR085056A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
EP4252755A3 (en) Therapeutic compounds
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BRPI0516810A (pt) uso de conjugados de lipìdios no tratamento de doenças
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
ES2974187T3 (es) Uso de 5-amino-2,3-dihidro-1,4-ftalazindiona en el tratamiento inhalatorio de enfermedades pulmonares inflamatorias
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.
AR062582A1 (es) Variedades polimorficas de derivados de 1-azonia-biciclo-[2.2.2]-octano